Company profile for Amydis

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Amydis is the leader in a new class of retinal diagnostics that are poised to revolutionize the early detection and treatment of neurodegenerative diseases, as well as the clinical evaluation of novel therapeutics.Amydis is developing novel diagnostic drugs that enable the detection of neurodegenerative diseases through the retina. The retina is part of the CNS and provides an accessible means to diagnose and track diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
10210 Campus Point Dr #150, San Diego, CA 92121,
Telephone
Telephone
858.707.5352
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Arvo

Arvo

Not Confirmed

envelop Contact Supplier

Arvo

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.indianpharmapost.com/biotech/amydis-bags-25-million-nih-grant-to-develop-first-eye-test-for-key-als-biomarker-19364

INDPHARMAPOST
14 Mar 2026

https://www.prnewswire.com/news-releases/seeing-als-through-the-eye-amydis-receives-phase-2-nih-grant-award-to-advance-a-novel-approach-to-detect-biomarker-tdp-43-302710770.html

PR NEWSWIRE
11 Mar 2026

https://www.globenewswire.com/news-release/2024/10/10/2961341/37146/en/Amydis-to-Present-First-Ocular-Tracer-Designed-to-Detect-Transthyretin-Amyloidosis-ATTR-at-AAOOP-Conference.html

GLOBENEWSWIRE
10 Oct 2024

https://www.globenewswire.com//news-release/2023/11/14/2779892/37146/en/Amydis-Receives-3-4-million-NIH-Commercialization-Readiness-Pilot-Grant-Award-to-Map-Heterogeneity-of-Alzheimer-s-Diseases-in-Human-Clinical-Trial-Using-Novel-Retinal-Tracer.html

GLOBENEWSWIRE
14 Nov 2023

https://www.globenewswire.com//news-release/2023/11/02/2772102/37146/en/Amydis-Launches-Phase-2-Glaucoma-Clinical-Program-Using-Novel-Retinal-Tracer-to-Detect-Amyloid-Beta.html

GLOBENEWSWIRE
02 Nov 2023

https://www.globenewswire.com/news-release/2023/02/21/2611806/37146/en/Amydis-Announces-Enrollment-of-Cerebral-Amyloid-Angiopathy-Participants-in-Phase-1-2a-Retinal-Tracer-Trial.html

GLOBENEWSWIRE
21 Feb 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty